Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia
pharmafile | December 9, 2019 | News story | Research and Development, Sales and Marketing | ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax
AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax in combination with rituximab (VenR) in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
The data, harvested following the completion of the MURANO trial, examined participants who had been off venetoclax for a median of 22 months. It was discovered that those who underwent a chemo-free VenR regimen with fixed treatment duration of two years maintained progression-free survival (PFS) and overall survival (OS) compared with a standard of care regimen of bendamustine plus rituximab (BR).
Progression-free survival rates stood at 68% 24 months following treatment, while overall survival rates at four years for VenR patients stood at 85.3% compared to 66.8% for BR patients.
Additionally, VenR patients achieved higher rates of complete remissions and undetectable minimal residual disease (uMRD) – defined as one CLL cell for every 10,000 white blood cells in the blood or bone marrow following treatment; 64% had achieved uMRD, with 87% remaining disease-free two years later.
“In the four-year analysis from the MURANO trial, treatment with the venetoclax combination resulted in an 81% reduction in the risk of progression or death compared to the standard of care,” said Dr Professor John Seymour, lead investigator of the MURANO trial and Director of the Department of Hematology at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Australia. “The sustained efficacy and manageable safety profile observed in the study further support the clinical benefits of fixed treatment in patients with relapsed or refractory chronic lymphocytic leukaemia.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
